journal article·2018-11-05Open access

Synthesis, characterization and in vitro/in vivo evaluation of novel reduction-sensitive hybrid nano-echinus-like nanomedicine

Kaili Wang, Chunjing Guo, Shaohua Zou, Yueming Yu, Xinxin Fan, Bingjie Wang, Mengna Liu, Lei Fang, Daquan Chen

Abstract

To remedy the problems resulting from the usage of anti-cancer drugs in cancer chemotherapy, such as deficient drug concentration in tumour cells, low water-solubility and non-specific distribution of antitumour drugs, a kind of reduction-sensitive polymer prodrug of curcumin (Cur) containing in the nano-echinus was synthesized and designed. The nano-echinus-like nanomedicine presented synergistic effect with glycyrrhetic acid (GA) and oligomeric hyaluronic (HA) for targeting and combating HepG2 human liver cancer cell. Firstly, a kind of small molecular prodrug of Cur, dithiodipropionic acid-Cur (-SS-Cur), was chemically conjugated onto the side chain of the conjugated glycyrrhetic acid- oligomeric hyaluronic (GA-HA) to generate an amphiphilic polymeric prodrug of Cur, GA-HA-SS-Cur. The obtained GA-HA-SS-Cur prodrug and subsidiary material mPEG-DSPE could self-assemble into a sea urchin-like micelles in aqueous media and release Cur rapidly in response to glutathion (GSH). Then, Cur was loaded into the nano-echinus with a particle size of (118.1 ± 0.2 nm) and drug-loading efficiency of (8.03 ± 2.1%). The structure of GA-HA-SS-Cur was characterized by 1H-NMR in this report. The morphology of micelles was observed with a transmission electron microscope (TEM). Subsequently, the reduction-sensitivity of the nano-echinus was confirmed by the changes in in-vitro drug release after different concentrations of GSH treatment. Besides, the cellular uptake behaviour and MTT assays of the nano-echinus were investigated, suggesting that the nano-echinus was of desirable safety and could be taken into HepG2 cells in a time-dependent manner. Later, anti-tumour efficacy in vivo revealed the effective inhibition of tumour growth.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Curcumin's Biomedical Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, Universities of Shandong, Yantai University, Yantai, PR China;

Department of Pharmaceutics, Yantai Yuhuangding Hospital, School of Medicine, Qingdao University, Yantai, PR China

Funding

the National Natural Science Foundation of China · Taishan Young Scholar Program

References (23)

Show source-provided references
1. 10.1080/10717544.2017.140656110.1080/10717544.2017.1406561 ↗
2. 10.1080/10717544.2017.127923810.1080/10717544.2017.1279238 ↗
3. 10.1021/acs.molpharmaceut.5b0067710.1021/acs.molpharmaceut.5b00677 ↗
4. 10.18632/oncotarget.608410.18632/oncotarget.6084 ↗
5. 10.1016/j.bmc.2018.02.02110.1016/j.bmc.2018.02.021 ↗
6. 10.1016/j.bmc.2017.08.00210.1016/j.bmc.2017.08.002 ↗
7. 10.1016/j.bmc.2007.05.05710.1016/j.bmc.2007.05.057 ↗
8. Satomi Y · Anticancer Res · 2005 · 25 · 4043
9. 10.1039/C6RA01580H10.1039/C6RA01580H ↗
10. 10.3390/md1109351710.3390/md11093517 ↗
11. 10.1007/s00396-014-3429-z10.1007/s00396-014-3429-z ↗
12. 10.1016/j.msec.2017.02.03010.1016/j.msec.2017.02.030 ↗
13. 10.1016/j.actbio.2017.12.02810.1016/j.actbio.2017.12.028 ↗
14. 10.1016/j.carbpol.2017.03.03110.1016/j.carbpol.2017.03.031 ↗
15. 10.1002/adma.20140070310.1002/adma.201400703 ↗
16. 10.1039/C7CS00492C10.1039/C7CS00492C ↗
17. XiaHou F · Acta Biomater · 2017 · 68 · 308
18. 10.1016/j.msec.2017.03.12410.1016/j.msec.2017.03.124 ↗
19. 10.1080/21691401.2017.141639010.1080/21691401.2017.1416390 ↗
20. 10.1016/j.ijbiomac.2017.12.06910.1016/j.ijbiomac.2017.12.069 ↗
21. 10.1016/j.carbpol.2017.05.03410.1016/j.carbpol.2017.05.034 ↗
22. 10.1016/j.ijbiomac.2017.11.00210.1016/j.ijbiomac.2017.11.002 ↗
23. 10.1002/mabi.20150031710.1002/mabi.201500317 ↗